All In Biotech

Drug Trial Radar · NCT06826196

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

A Phase 1B/2A, Intraindividual Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution for Intradermal Injection in Subjects With Alopecia Areata

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

9

Actual

Start

Mar 24, 2025

Primary completion

Nov 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Aldena TherapeuticsIndustry
Sponsor type
Industry
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjects with alopecia areata. The study will also learn about the effect of ALD-102 on hair regrowth in treatment areas. The researchers will compare the effects of ALD-102 Solution (drug) to placebo (saline solution that contains no drug) or an untreated area. Study participants will have treatment areas selected on the scalp to receive ALD-102 Solution (drug), placebo (saline solution) or to remain untreated. Injections will occur once every 4 weeks for a treatment period of 8 weeks.

Conditions

  • Alopecia Areata (AA)

Interventions

  • ALD-102 SolutionDrug

    Treatment every 4 weeks for total of 8-week treatment period.

  • Placebo or ControlOther

    Treatment every 4 weeks for 8-week treatment period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse effects (AEs) and severe adverse effects (SAEs) as assessed by CTCAE, and injection site reactions (ISRs), evaluated by local tolerability assessments and numerical scales.Time frame: Clinical assessments during treatment and follow up period for a total of 24 weeks.

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinical Trial Research Institute

    Thousand Oaks, California

  • Options Research Group

    West Lafayette, Indiana

  • The Brigham and Women's Hospital

    Boston, Massachusetts

  • Lahey Clinic

    Burlington, Massachusetts

  • Dermatology Specialists of Spokane

    Spokane, Washington

  • The Centre for Clinical Trials

    Oakville, Ontario, Canada

  • Innovaderm

    Montreal, Quebec, Canada

  • Centre de Recherche Saint-Louis

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.